141 related articles for article (PubMed ID: 35154933)
1. Evaluation of Diagnostic Utility of the Immunohistochemical Markers in the Accurate Diagnosis of Thyroid Neoplasms: A Retrospective Study in a Tertiary Care Hospital of Pakistan.
Badini K; Fatima S; Khan SA; Suchal Z; Islam N
Cureus; 2022 Jan; 14(1):e20953. PubMed ID: 35154933
[TBL] [Abstract][Full Text] [Related]
2. Epithelial markers in thyroid carcinoma: an immunoperoxidase study.
Wilson NW; Pambakian H; Richardson TC; Stokoe MR; Makin CA; Heyderman E
Histopathology; 1986 Aug; 10(8):815-29. PubMed ID: 2428725
[TBL] [Abstract][Full Text] [Related]
3. [Immunohistochemical analysis of malignant tumors of the thyroid gland using 6 relevant markers].
Brasanac D; Jancić-Zgurics M; Janković R; Tatić S
Srp Arh Celok Lek; 1993; 121(3-7):70-3. PubMed ID: 7716641
[TBL] [Abstract][Full Text] [Related]
4. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
5. Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases.
Wenig BM; Thompson LD; Adair CF; Shmookler B; Heffess CS
Cancer; 1998 Feb; 82(4):740-53. PubMed ID: 9477108
[TBL] [Abstract][Full Text] [Related]
6. Expression of HBME-1 and CD56 in follicular variant of papillary carcinoma in children: An immunohistochemical study and their diagnostic utility.
Skaria PE; Ahmed AA; Yin H; Nicol K; Reid KJ; Singh V
Pathol Res Pract; 2019 May; 215(5):880-884. PubMed ID: 30711197
[TBL] [Abstract][Full Text] [Related]
7. Study of Immunohistochemical Markers (CK-19, CD-56, Ki-67, p53) in Differentiating Benign and Malignant Solitary Thyroid Nodules with special Reference to Papillary Thyroid Carcinomas.
Dwivedi SS; Khandeparkar SG; Joshi AR; Kulkarni MM; Bhayekar P; Jadhav A; Nayar M; Kambale NS
J Clin Diagn Res; 2016 Dec; 10(12):EC14-EC19. PubMed ID: 28208864
[TBL] [Abstract][Full Text] [Related]
8. Tumor markers and oncogene expression in thyroid cancer using biochemical and immunohistochemical studies.
Hashimoto T; Matsubara F; Mizukami Y; Miyazaki I; Michigishi T; Yanaihara N
Endocrinol Jpn; 1990 Apr; 37(2):247-54. PubMed ID: 1699752
[TBL] [Abstract][Full Text] [Related]
9. CD56 expression in benign and malignant thyroid lesions.
Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N
Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227
[TBL] [Abstract][Full Text] [Related]
10. A study of FoxA1 expression in thyroid tumors.
Nonaka D
Hum Pathol; 2017 Jul; 65():217-224. PubMed ID: 28546130
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
12. [Cytokeratin expression of benign and malignant epithelial thyroid gland tumors. An immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies].
Schröder S; Wodzynski A; Padberg B
Pathologe; 1996 Nov; 17(6):425-32. PubMed ID: 9082363
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry Helps to Distinguish Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features/Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Other Follicular Thyroid Lesions.
Chuang HW; Wang JS; Tsai JW; Hsu CT; Lin KJ
Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833464
[No Abstract] [Full Text] [Related]
14. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.
Tan A; Etit D; Bayol U; Altinel D; Tan S
Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633
[TBL] [Abstract][Full Text] [Related]
15. Histopathological and Immunohistochemical Characteristics of Thyroid Carcinoma in the Dog.
Soares LMC; Pereira AHB; de Campos CG; Rocha LS; Dos Santos TÁ; Souza MA; Jark PC; Pescador CA
J Comp Pathol; 2020 May; 177():34-41. PubMed ID: 32505238
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential.
Nechifor-Boilă A; Cătană R; Loghin A; Radu TG; Borda A
Rom J Morphol Embryol; 2014; 55(1):49-56. PubMed ID: 24715165
[TBL] [Abstract][Full Text] [Related]
17. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules.
Beesley MF; McLaren KM
Histopathology; 2002 Sep; 41(3):236-43. PubMed ID: 12207785
[TBL] [Abstract][Full Text] [Related]
19. Thyroid cancer: a lethal endocrine neoplasm.
Robbins J; Merino MJ; Boice JD; Ron E; Ain KB; Alexander HR; Norton JA; Reynolds J
Ann Intern Med; 1991 Jul; 115(2):133-47. PubMed ID: 2058861
[TBL] [Abstract][Full Text] [Related]
20. Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms.
Bejarano PA; Nikiforov YE; Swenson ES; Biddinger PW
Appl Immunohistochem Mol Morphol; 2000 Sep; 8(3):189-94. PubMed ID: 10981870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
